Objectives: This paper aims to compare changes over 2 years in patients' healthrelated quality of life (HRQL) with the health and social care costs of diagnosis and treatment of people newly referred to memory assessment services (MAS).
suspected dementia to memory assessment services (MAS) has been advocated and implemented in many high-income countries. These services usually involve an integrated multi-professional approach to diagnosis and management of dementia. However, the structural characteristics (eg, staff composition) and the services provided by MAS (eg, post-diagnostic support) vary considerably both within and between countries. 2 In England, services typically consist of a team of doctors, psychologists, nurses, occupational therapists, and community support workers that provide specialist assessment, diagnosis, and treatment to patients with suspected dementia following a general practitioner (GP) referral. The extent of variation in the structure and activities in English MAS has recently been reported. 5 Given the variation in provision and uncertainties about the impact of MAS on patients' health-related quality of life (HRQL), there is a need for evidence on the relative effectiveness and costeffectiveness of these services. 6, 7 In particular, the benefits of a more integrated approach for diagnostic and postdiagnostic services is largely unknown. 8 This lack of evidence partly reflects the challenges of evaluating memory services, which involve a wide range of diagnostic and treatment components. In addition, dementia care pathways often differ within health care systems, 2 which makes the comparison between studies evaluating MAS difficult.
Against this background, evidence from randomised trials is rare and tends to focus on evaluating specific components of memory services compared with no intervention. The main challenge to evaluating the full dementia care pathway through randomised trials is the impossibility of a "control" group because of ethical objections to delaying referral (or treatment) of people with suspected dementia. For example, a recent trial in the Netherlands, the AD-Euro study, 9 compared dementia care provided by MAS versus general practitioners. However, this trial only compared models for postdiagnostic care and did not assess the impact of MAS on patients' HRQL and health care costs from the first assessment through diagnosis and treatment. Another trial, the MEDICIE study, 10 compared an integrated multidisciplinary diagnostic approach by a specialist team (community mental health team and geriatric psychiatrist) with GP (control arm). However, those patients randomised to the control group were either diagnosed by the GP or referred to regional memory or geriatric clinics, or regional mental health teams. Evidence from nonrandomised studies on the effectiveness and cost-effectiveness of MAS is also scarce. Most published studies focused on a single MAS 11, 12 or on modelling projections. 13 Our aim was to determine the effectiveness and costeffectiveness of MAS in a large representative sample of sites in order to obtain generalizable evidence and identify the extent of variation that exists. We conducted a longitudinal study that followed up 1318 patients referred to 69 MAS in England. 14 In previous papers, we reported HRQL, 15 costs, 16 and cost-effectiveness 17 between first assessment and 6 months. The studies reported that MAS improved patient's HRQL, according to both disease-specific and generic HRQL instruments, irrespective of the severity of peoples' cognitive impairment. While there was little variation in outcome between MAS, there was considerable variation in costs 16 and cost-effectiveness. 17 However, the sustainability of such changes over a longer time period is unknown. In this paper, we report the relative costs and outcomes of MAS for the diagnosis, treatment, and follow-up care up to 2 years after first consultation. We examine whether the cost-effectiveness of MAS differs according to key characteristics of the patients and the memory clinics.
2 | METHODS
| Study design
Full details on the sampling, recruitment, and data collection methods are reported elsewhere. 14, 17 Briefly, the study included 69 MAS, a ran- who provided consent for follow up (N = 1318) were included in the study regardless of the diagnosis they later received (ie, whether or not they were labelled as having dementia). For practical reasons, at 24 months, the follow-up was restricted to the 30 MAS with the highest recruitment rates at baseline. Previously, we had observed that outcomes were not associated with size of MAS or recruitment rates. 14 At 24 months, 643 patients and 467 carers were eligible for inclusion.
Patients were interviewed at baseline and asked to report on their sociodemographic characteristics, disease-specific HRQL (DEMQOL), and generic HRQL (EQ-5D-3 L). Carers also completed a separate baseline questionnaire that included self-reported HRQL (generic and disease-specific), carer burden, proxy-reported HRQL of the patient, and resources used in the last 4 weeks. Patients and carers who were willing to continue in the study attended a follow-up appointment (at the clinic or patient's home) at 6, 12, and 24, and reported on their HRQL and burden of care. Carers were also mailed resource use questionnaires at 3, 6, 12, and 24 months. All follow-up questionnaires were identical to baseline, except the 24-month Key summary points
• Attending memory assessment services (MAS) is associated with improvement in people's health-related quality of life.
• Costs vary considerably between clinics but MAS can be cost-effective for the diagnosis and treatment of patients with suspected dementia.
• There is a need for many MAS to improve their operational efficiency and learn from those that achieve similar health outcomes but at lower cost.
resource use questionnaire, which was simplified (excluded details about intensity of contacts with health care professionals, which was assumed to be similar to that at 6 months). The EQ-5D-3 L is a generic measure of health status and includes five items covering different health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression (scored on an itemspecific three-point scale). The EQ-5D-3 L profiles were combined with health state preferences values from the UK general population 20 to give EQ-5D-3 L utility scores, anchored at 0 (death) and 1 (perfect health). Although generic, this instrument has shown adequate reliability for measuring HQRL in patients with dementia.
22
Quality-adjusted life years (QALYs) were calculated by valuing each patient's survival time by their EQ-5D-3 L score at baseline, 6, 12, and 24 months according to the "area under the curve" approach.
To construct disease-specific QALYs based on DEMQOL, we have derived a preference-based score (DEMQOL-U) from the original DEMQOL measure, using a previously developed algorithm. 23 
| Costs
We reported costs related to four main components: (1) health care costs related to the use of both pharmacological (dementia drugs) and nonpharmacological treatments (eg, cognitive stimulation therapy and music/dance therapies); (2) use of social services, such as home care, cleaner, and meals on wheels; (3) informal care provided by relatives or friends; and (4) costs of services by the MAS, derived from proportion of time spent by staff on diagnostic assessment (including diagnostic tests), on postdiagnostic support, and on follow-up care.
Health care contacts with health care professionals such as GPs and nurses were not collected at 24 months for two reasons:
firstly,12 months after the first visit to the MAS, it was assumed that the use of such services would be unaffected by the involvement of MAS; and secondly, many of these health care contacts will be for reasons other than dementia, given the high prevalence of comorbidities.
Unit costs for health and social care professionals were taken from national costs sources. 24 Dementia drug costs were obtained from the British National Formulary (BNF, 2014). Psychosocial support services, such as cognitive stimulation therapy, art, and music therapies, were costed per session and unit costs taken from national sources and related literature. 24 Costs related to informal care were valued at £6 per hour based on the national minimum wage for 2013 to 2014. At the MAS level, staff use was valued using unit costs for health care professionals. 24 The costs of imaging and other diagnostic tests were taken from the NHS reference costs. 25 
| Cost-effectiveness
For the purposes of determining the cost-effectiveness of MAS, our analysis took a health services perspective and included costs related to drugs, primary care, and psychosocial interventions. We reported mean DEMQOL, EQ-5D-3 L, and patient costs at baseline and each follow-up. Any missing data were addressed using multiple imputation (see full details in Table S1 ). Mean differences in HRQL outcomes and total costs between baseline and 2 years were obtained, together with 95% confidence intervals (CI), using nonparametric bootstrapping (2000 bootstrap replications). We assessed the cost-effectiveness of
MAS by reporting incremental cost-effectiveness ratios (ICER) and incremental net monetary benefits (INB). The former corresponds to
the ratio between the incremental cost and incremental QALY, whereas the latter was obtained by valuing the incremental QALY by the willingness to pay threshold recommended by the National Institute for Health and Care Excellence (NICE) (£30 000 per QALY) and subtracting from this the incremental cost.
The base case analysis assumed that patients' HRQL (and costs)
would have remained constant between baseline and the 2-year follow-up had they not attended MAS. In sensitivity analysis, we considered alternative departures from this assumption. For example, we hypothesised that patients would have lower HRQL (EQ-5D-3 L and DEMQOL-U) because of deteriorating cognitive function had they not attended MAS. We considered decrements in HRQL of 1% (ageand sex-related HRQL decrement in the general population 26 ), 5%
and 10%.
We reported incremental cost and QALY and cost-effectiveness by patient (eg, age, sex, and ethnicity group) and MAS (eg, number of new patients per month, cost of MAS per patient, and whether MAS provided psychosocial support) subgroups. Mean differences in the net benefits between subgroups were adjusted for patient's sociodemographic characteristics and baseline HRQL. We have allowed for potential clustering by MAS using random effects models. 27 Uncertainty around adjusted differences in the net benefits was obtained from the bootstrap samples.
| RESULTS
Baseline patient and clinic characteristics and HRQL measures were mostly complete for all 1318 patients recruited (Tables S1 and S2 ).
Of 944 informal carers, resource use was reported for 830 (63%)
patients (374 patients did not have a carer in attendance at the first visit). At 12 months, both disease-specific and generic HRQL were reported for over 50% of patients, whereas resource use was available for only 35% of patients (Table S1) . At 24 months, the proportion of patients with reported outcomes (out of the total sample) was lower,
given that only 30 MAS were included in the longer-term follow-up. compared with that at baseline. Although primary care, psychosocial support, and informal care costs were higher at 2 years, the change was not statistically significant. At the MAS level, assessment costs comprised half of the total cost of memory services: mean cost was £886 (95% CI, 846-932) ( Table 3) . Over 2 years, the mean total cost per patient, which included drugs, primary care, and psychosocial interventions costs and the MAS's assessment, intervention, and review costs was £2411 (95% CI, 1721-2873).
At 24 months, patients referred to MAS experienced better quality of life according to all HRQL measures compared with baseline, but this was not statistically significant for the generic measure (EQ-5D-3 L) ( Table 2 ). For example, mean differences in DEMQOL-U was 0.027 (95% CI, 0.012-0.041) but for EQ-5D-3 L was 0.012 (95% CI, −0.011 to 0.039). The total QALYs gained by 2 years, based on the DEMQOL-U, was 0.04 (95% CI, 0.026-0.054) and on the EQ-5D-3 L was 0.027 (95% CI, 0.001-0.051) ( Table 3 ). This meant a cost per QALY of £59 975 and £89 546 according to gains in DEMQOL-U and EQ-5D-3 L, respectively. These ICERs are above the NICE's recommended threshold of £30,000 per QALY gain (incremental net benefits are negative).
Those estimates assume patients' HRQL would have remained unchanged over the 2-year follow-up if they had not received care initiated by a MAS. Subgroup analyses according to patient and clinic characteristics are summarised in Figure 1 and Table 5 , respectively. Incremental net benefits are similar by patient age, sex, socioeconomic status, and number of comorbidities (Figure 1) . Non-white patients benefit less from memory services than white patients, though because of the small sample size, the confidence interval was very large. Larger MAS, with an average number of patients per month above 50
were statistically significantly more cost-effective than MAS with 25 or fewer monthly new patients. These differences were mostly due to lower incremental costs (economies of scale) rather than outcome differences. Not surprisingly, MAS with lower cost per new patient (below £2500) were relatively more cost-effective (P values < 0.01), because these were associated with a considerably lower average total cost.
For example, adjusted mean difference in the net benefits between MAS in the 5th and 4th quintile was £1464 (95% CI, 933-1993). Abbreviations: SA1, Age and sex-related decrement (~1%) in EQ-5D-3 L over the 2-year period; SA2, 5% decrement in EQ-5D-3 L over the 2-year period; SA3, 10% decrement in EQ-5D-3 L over 2-year period.
a Confidence intervals were obtained by non-parametric bootstrapping (2000 replications).
FIGURE 1
Incremental net monetary benefits (at £30 000 per QALY) at 24 months by patient subgroups. P values are derived from adjusted mean differences in the net benefits between the different subgroups and the reference category. These differences were adjusted for age, sex, ethnicity, deprivation, number of comorbidities, baseline EQ-5D-3 L, and clustering by clinic Assuming a health services perspective, the total cost accrued up to 2 years included health care (dementia drugs, psychosocial interventions, and primary care) costs, and the MAS' assessment, intervention, and review costs up to 24 months. Incremental net benefit (INB) is calculated by multiplying the mean QALY by the willingness to pay threshold recommended by the National Institute for Health and Care Excellence (NICE) (£30 000 per QALY) and subtracting from this the mean total cost. Incremental cost-effectiveness ratio (ICER) is calculated by dividing mean total cost by mean QALY.
Our short-term cost-effectiveness analysis 17 reported that patients attending MAS had a QALY gain according to DEMQOL-U of 0.021 and EQ-5D-3 L of 0.023 over the first 6 months after referral. This study shows that the improvement in HRQL is maintained to 2 years, although the EQ-5D-3 L gain is smaller (0.014) than at 6 months (0.023). However, as the HRQL gain is sustained for an additional 18 months, the QALY gain at 2 years has increased four-fold from 0.006 to 0.027. Given that most of the costs associated with MAS are incurred in the first 6 months after the first consultation, the difference in mean total cost at 6 and 24 months is not very large (£1899 vs £2411). Overall, the continuous HRQL gain and small rise in total costs at 2 years increased considerably the likelihood of memory services being cost-effective.
These findings are consistent with a previous calculation of the cost-effectiveness of memory services in England. 13 Using a costeffectiveness model, the study suggested that MAS were likely to be cost-effective if QALY gain (per person year) was above 0.01. We have observed a gain well above that. While Banerjee and
Wittenberg's projections included potential cost savings from reduced use of residential care (not considered in our study), their model did not include the direct costs related to diagnosis. This is the first study reporting on the cost-effectiveness of memory services over a 2-year follow-up. There are several strengths to this paper. Firstly, the cost-effectiveness analysis is based on the largest observational study of patients referred to MAS in England. Unlike previous studies focussing on a single memory clinic, 11, 12, 31 our sample is representative of MAS across all regions in the country and in terms of other organisational features. 14 Secondly, this study reports on the cost-effectiveness of MAS providing a broad, integrated approach to diagnosis, treatment, and follow-up care of patients with dementia. This is in contrast with previous cost-effectiveness studies focussing on particular components of care, such as diagnosis 10 or follow-up care. 32 Thirdly, this economic evaluation is based on rigourous collection of data on different measures of effectiveness (both disease-specific and generic HQRL measures), and costs to the NHS, social care, carers, and patients (societal perspective). Fourthly, our cost-effectiveness findings are based on longitudinal measurements of both costs and outcomes over 2 years, and hence, captures Mean differences in net benefits were adjusted for age, sex, ethnicity, deprivation, number of comorbidities, baseline EQ-5D, clinic characteristics considered in this table, and clustering within clinics (using multilevel linear regression).
the impact of MAS over a longer period than previous studies based on a single time point and short follow up: either 3 months, 31 6 months, 17 or 1 year. 10, 32 There are three main limitations to this study. First, our study did not include a comparison (control) group. The immediate implication is that we had to make an assumption about what would have been patients' costs and outcomes at 2 years had they not been referred to MAS. In our main analysis (base-case), we assumed that patients' HRQL and costs have remained constant over the 2-year period. This may be plausible for costs because had patients not attended MAS, they were likely to have remained undiagnosed and continued to receive the same level of care as before. However, based on previous studies, the HRQL of patients receiving standard (usual) care is likely to deteriorate over time. 10, [28] [29] [30] In sensitivity analysis, we have allowed for up to 10% reductions in HRQL over time, and found that the study's conclusions are sensitive to these assumptions.
Second, as with other studies based on self-reported outcome measures or proxy-reported resource use questionnaires, our study had a considerable proportion of individuals with missing HRQL or cost data. We have used a widely recommended approach, multiple imputation, for handling missing data in cost-effectiveness analysis. 33, 34 This approach assumes that any differences between patients with observed and missing data can be explained (and adjusted for) by the observed data (missing-at-random assumption). Accordingly, we have included in our imputation model a wide range of likely missing data predictors, such as baseline patient and MAS characteristics, follow-up process measures and observed endpoints. In addition, the imputation model recognised that the chances of observing the data were more similar within than across MAS.
Third, data on resource use at 24 months were collected using a simplified version of the questionnaire completed by carers at baseline, 3, 6, and 12 months. Thus, the questionnaire only asked carers to indicate if there had been any contact with a health care professional but did not seek details about the intensity of any contact.
We therefore had to estimate costs attributable to each contact with health professionals according to median values derived from responses to the 6-month questionnaire. Overall, this may have resulted in a slight overestimation of the health and social care costs at 24 months.
The key implication of our findings for policy and practice is the need for a sizeable proportion of MAS to review their costs and learn from MAS that achieve similar outcomes but at lower cost. Our study suggests that having large multidisciplinary teams is associated with As regards further research, it would be interesting to incorporate carer's own HRQL gains into the economic evaluation of MAS as this may provide additional benefits that the current analysis does not take into account. A second avenue to pursue would be to explore even longer follow-up to establish whether the benefits are sustained for even longer than 2 years.
In conclusion, the early diagnosis and treatment of dementia is at the core of national dementia strategies in many countries. Our study suggests that a model of care based on English MAS is effective and may be cost-effective for the diagnosis, treatment, and follow-up care of patients with dementia. Patients' HRQL gains are maintained 2 years after referral and may be sufficient to warrant the costs involved in providing memory services. Under realistic assumptions about the consequences of no treatment, the cost per QALY of MAS comes within NICE's recommended threshold of £20 000 to £30 000 per QALY gain.
